MIA PaCa-2 (ATCC® CRM-CRL-1420)

Organism: Homo sapiens, human  /  Cell Type: epithelial cell (KRAS CRM)  /  Tissue: pancreas  /  Disease: carcinoma

Organism Homo sapiens, human
Tissue pancreas
Cell Type epithelial cell (KRAS CRM)
Product Format frozen
Morphology attached epithelial with floating rounded cells
Culture Properties adherent, single cells and loosely attached clusters
Biosafety Level 1
Disease carcinoma
Age 65 years
Gender Male
Ethnicity Caucasian
Applications
For use in testing and calibration in ISO 17025 accredited laboratories, to challenge assay performance, validate or compare test methods, and to establish sensitivity, linearity and specificity during assay validation or implementation. ISO Guide 34:2009
Intended Use


Certified Reference Material produced under an ISO Guide 34:2009 accredited process. 


    ACLASS Accredited Reference Material Producer AR-1384

Storage Conditions liquid nitrogen vapor phase
Karyotype This is a hypotriploid human cell line. The modal chromosome number is 61. Sixteen to 20 marker chromosomes are commonly found in a cell. A few normal chromosomes are absent.
Derivation
The MIA PaCa-2 cell line was established by A. Yunis, et al. in 1975 from tumor tissue of the pancreas obtained from a 65-year-old Caucasian male.
Hybridomas have been made against the CSF-I produced by this line ATCC HB-8207 (F1A3-23) and ATCC HB-8208 (F18 AF1).
Clinical Data
65 years
Caucasian
male
Genes Expressed
human colony stimulating factor, subclass I (CSF-I); plasminogen activator
Comments Certificates of Analysis are available electronically at www.atcc.org, or by hardcopy upon request.

Certified Reference Material produced under an ISO Guide 34:2009 accredited process. 

Item has been tested for KRAS mutation (p.G12C c.34G>T)

The established cell line reportedly has a doubling time of about 40 hours and a colony-forming efficiency in soft agar of approximately 19%.

The line is sensitive to asparaginase.

Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%; horse serum to a final concentration of 2.5%.
Subculturing
Protocol: Remove medium, and rinse with 0.25% trypsin, 0.53 mM EDTA solution. Remove the solution and add an additional 1 to 2 mL of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37°C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:8 is recommended
Medium Renewal: 2 to 3 times per week
Cryopreservation
Freeze Medium: Complete growth medium 95%; DMSO, 5%
Storage Temperature: Liquid nitrogen vapor phase
Culture Conditions
Temperature: 37°C
STR Profile
Amelogenin: X
CSF1PO: 10
D13S317: 12,13
D16S539: 10,13
D5S818: 12,13
D7S820: 12,13
THO1: 9,10
TPOX: 9
vWA: 15
Isoenzymes
G6PD, B
Name of Depositor A Yunis
Year of Origin 1975
References

Wu M, et al. Purification and characterization of a plasminogen activator secreted by cultured human pancreatic carcinoma cells. Biochemistry 16: 1908-1913, 1977. PubMed: 15590

Fountzilas G, et al. Comparative effects of selected drug combinations on the growth of a human pancreatic carcinoma cell line (MIA PaCa-2). J. Natl. Cancer Inst. 76: 37-43, 1986. PubMed: 3455740

Robertson JF, et al. Effect of gastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer. Int. J. Cancer 63: 69-75, 1995. PubMed: 7558455

Yunis AA, et al. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int. J. Cancer 19: 128-135, 1977. PubMed: 832918

Basic Documentation
FAQ's
  1. Agreement to transfer to a CRO


    Date Updated: 1/2/2013

References

Wu M, et al. Purification and characterization of a plasminogen activator secreted by cultured human pancreatic carcinoma cells. Biochemistry 16: 1908-1913, 1977. PubMed: 15590

Fountzilas G, et al. Comparative effects of selected drug combinations on the growth of a human pancreatic carcinoma cell line (MIA PaCa-2). J. Natl. Cancer Inst. 76: 37-43, 1986. PubMed: 3455740

Robertson JF, et al. Effect of gastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer. Int. J. Cancer 63: 69-75, 1995. PubMed: 7558455

Yunis AA, et al. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int. J. Cancer 19: 128-135, 1977. PubMed: 832918